Navigation Links
The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Date:2/19/2013

tologic malignancies with a unique link to the cancer research community. Many innovations such as multi-drug chemotherapy and stem cell transplantation started as blood cancer therapies. In fact, nearly 50 percent of all cancer drugs newly approved by the US Food & Drug Administration (FDA) in the last 12 years were first approved for blood cancers. "Blood cancer research is a gateway to treatments and even cures for many other cancers, as well as some inflammatory diseases, such as rheumatoid arthritis (RA)," explains DeGennaro. "LLS and our partners are pioneering cutting-edge cancer research at the cellular and molecular level, which has the capacity to offer significant contributions beyond even blood cancers."

"Someday is Today"

"We felt it was time to put a stake in the ground, and to shine the spotlight on the urgency and accomplishments we have made toward finding cures for blood cancers. 'Someday is Today' is our platform to rally support for this cause," explains John Walter , LLS chief executive officer. "People talk about curing cancer at some point in the future.  But, for LLS, someday is today. Contributions made to this organization – through partners, volunteers and generous donors – are driving cures right now. The reality is, if you want to reduce the incidence of lung cancer, stop smoking.  If you want to reduce the incidence of melanoma, use sun block. If you want to prevent the incidence of blood cancer, invest in a cure."

The "Someday is Today" initiative will launch this month nationwide, with emphasis in New York, Chicago, Los Angeles, San Francisco, Washington DC, and Dallas. The platform was developed by LLS in conjunction with branding agency Interplanetary, and is being supported by TV and radio
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
2. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
3. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
4. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
5. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
6. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
7. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
8. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
9. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
10. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... This is a professional and in-depth ... Hardener industry in Global and China. The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... Pittcon is pleased to announce that the ... Horiba Scientific, have organized a session on nanotechnology for ... , Asia’s largest analytical and scientific instruments show, will ... , The four speakers in this U.S. symposium, ... to Single Cells” will present their use of nanotechnology ...
Breaking Biology Technology:Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... Authentication ... This presentation identifies key challenges facing manufacturers of ... technology is being leveraged to overcome ... that enhances safety and reliability, increases revenue and brand ...
... 11 , - TB-402 Shows Clear Promise ... Thromboembolic Disorders., ThromboGenics NV (Euronext Brussels:THR), a ... that the results of the,first Phase I trial ... Society of Hematology (ASH) 49th Annual Meeting in ...
... TTG ), a leading manufacturer of sterile biological implant ... results for the fiscal year and fourth quarter ended September,30, ... fiscal year include:, -- Total fiscal year 2007 ... increased 38% in fiscal year 2007; -- Sales ...
Cached Biology Technology:SkyeTek to Present Webinar on Transforming the Management of Medical Devices & Supplies with Embedded RFID 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 2Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 5Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 6Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 7Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 8Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 9Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 10
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
(Date:8/29/2014)... fold them: modern materials that are light, flexible and ... skin or electronic paper. , Making such concepts affordable ... new way of working with copper nanowires and a ... Previous success in the field of ultra-lightweight "aerogel monoliths" ... and silver nanowires. , By turning instead to ...
(Date:8/28/2014)... called TX Invasives is now available from the Lady ... at Austin for identifying harmful non-native plant, insect and ... the United States cause about $137 billion in economic ... clog waterways, kill native plants and more. , "By ... reporting where invasive species occur, we,re more likely to ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Copper shines as flexible conductor 2Mobile app makes ID of harmful plants, insects in Texas a snap 2
... available in German . ... have jaws have four fins or limbs, one pair in front ... of evolution, into a marvelous variety of fins, legs, arms, flippers, and ... arrangement of two pairs of appendages? Because we have a belly. ...
... Yale School of Medicine researchers provides insight into how much ... reproductive health. Published in the Jan. 27 issue of ... of reproductive-age women had never discussed their reproductive health with ... provider less than once a year or never. ...
... embryonic stem cells of high clinical quality. It also allows ... The discovery is a big step forward for stem cell ... and thereby curing serious illnesses such as diabetes and Parkinson,s ... from surplus in vitro fertilized (IVF) embryos that are not ...
Cached Biology News:How did we get 4 limbs? Because we have a belly 2How did we get 4 limbs? Because we have a belly 3The science of baby-making still a mystery for many women 2New method increases supply of embryonic stem cells 2
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Polyclonal Antibody to SHPRH...
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Biotin anti-mouse Ly-49C/F/I/H...
Biology Products: